The phase 1 study is ongoing, with the next cohort to be dosed at 1mg/kg. The target here is to reduce misfolded transthyretin by at least 90%. The trial will follow patients for up to two years, which should give an idea of any off-target effects and durability – Crispr editing is designed to be permanent, but then so is gene therapy.
A packet of Crisprs
No information on patients’ disease progression or quality of life changes is yet available. But, for now, that does not really matter: it is the proof that Crispr can work that has electrified the market. Other Crispr players have seen marked share price rises as investors consider the technology at least partly derisked.
|Other players in the nascent In vivo gene editing space|
|Company||Early stock reaction||Market cap||Next in vivo gene editing news|
|Editas||up 10%||$3.4bn||Data due by year end from Brilliance trial of EDIT-101 in Leber congenital amaurosis 10 (non-systemic delivery).|
|Precision Biosciences||up 8%||$717m||Update due mid-year on IND and clinical plans for first programme, in primary hyperoxaluria type 1.|
|Beam Therapeutics||up 17%||$6.8bn||IND for lead project, in sickle cell disease, to be filed in H2'21.|
|Verve||up 27%||$2.0bn||IND for lead project, in HeFH, to be filed in 2022.|
|Crispr Therapeutics||up 8%||$11.5bn||Four projects in research stage|
|Source: Company statements.|
The challenge for these other players is not so much successfully editing genes so much as managing to get their agents to the right location. Transthyretin amyloidosis is relatively easy in this regard – the protein is made in the liver, so this is where NTLA-2001 was delivered and made its effects felt. Intellia’s next project is aimed at knocking down the gene for prekallikrein B1 as a therapy for hereditary angioedema; this protein is also produced in the liver.
More diffuse diseases or hard to reach organs, such as cystic fibrosis or heart disease, could be trickier prospects. There is also the fact that knocking down a gene, as Intellia has done, is thought to be easier than repairing a faulty one.
If Intellia’s success has implications for the other Crispr companies, it has different ramifications for non-Crispr groups. Companies developing RNA interference for oligonucleotide projects aimed at liver disease now have a new competitive threat.
Alnylam is one such example. It sells an IV RNAi therapeutic, Onpattro, for the polyneuropathy subtype of transthyretin amyloidosis, and has filed a similar subcutaneous product, vutrisiran. The company opened off 6% today.
There is much work ahead for Intellia and its competitors before the commercial future of in vivo Crispr therapies becomes clear. For a start, regulators need to be persuaded to allow more projects to move into the clinic; Precision and Beam will be the next to ask the FDA permission to begin trials, and green lights would provide another boost to this field.
But with clear signs of efficacy and no safety concerns, Intellia's first-glimpse clinical data was probably the best start the field could have hoped for.